文献速递神经介入CTMRDSA

大梗死核心急性卒中血管内治疗的美国成本效益分析

Cost-effectiveness of Endovascular Treatment for Acute Stroke with Large Infarct: A United States Perspective.
PubMed 文献 · Radiology · 2023-01-01

基于RESCUE-Japan LIMIT随机试验的二次分析,纳入基线ASPECTS 3-5的前循环大血管闭塞急性缺血性卒中患者202例,从美国医疗保健和社会角度评估血管内治疗联合最佳药物治疗与单纯最佳药物治疗的成本效益。血管内治疗联合最佳药物治疗的增量成本效果比(ICER)为15743美元(医疗保健角度)和19492美元(社会角度),在ASPECTS 4-5患者中具有成本效益,但在ASPECTS 3患者中不具有成本效益(ICER 337072美元和383628美元)。

要点

  • 对于基线ASPECTS 4-5的大梗死核心急性卒中患者,血管内治疗联合最佳药物治疗在美国背景下具有成本效益。
  • 对于基线ASPECTS 3的患者,血管内治疗联合最佳药物治疗不具有成本效益(ICER 337072美元和383628美元)。
  • 在支付意愿阈值50000和100000美元/QALY下,血管内治疗在医疗保健角度对 up to 85岁和90岁患者具有成本效益,社会角度对 up to 84岁和89岁患者具有成本效益。

核心结论

  • 对于ASPECTS 4-5的大梗死核心急性缺血性卒中患者,血管内治疗联合最佳药物治疗具有成本效益;但对于ASPECTS 3的患者不具有成本效益。

研究设计与样本

  • RESCUE-Japan LIMIT随机试验的二次分析,纳入2018年11月至2021年9月期间202例基线ASPECTS 3-5(基于平扫CT和弥散加权成像)的前循环大血管闭塞急性缺血性卒中患者,随机1:1接受血管内治疗联合最佳药物治疗(n=100)或单纯最佳药物治疗(n=102);采用包含短期成分(周期长度3个月)和长期Markov状态转换成分(周期长度1年)的决策模型,从美国医疗保健和社会角度估算终身成本和QALYs。

诊断标准与关键数值

  • 主要结局为增量成本效果比(ICER);支付意愿阈值上限为100000美元/QALY,下限为50000美元/QALY;血管内治疗联合最佳药物治疗的ICER为15743美元(医疗保健角度)和19492美元(社会角度);在较低和较高支付意愿阈值下,血管内治疗在医疗保健角度对85岁和90岁以下患者具有成本效益,在社会角度对84岁和89岁以下患者具有成本效益;ASPECTS 3患者亚组ICER为337072美元(医疗保健角度)和383628美元(社会角度)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The health economic benefit of endovascular treatment (EVT) in addition to best medical management for acute ischemic stroke with large ischemic core is uncertain. Purpose To assess the cost-effectiveness of EVT plus best medical management versus best medical management alone in treating acute ischemic stroke with large vessel occlusion and a baseline Alberta Stroke Program Early CT Score (ASPECTS) 3-5. Materials and Methods This is a secondary analysis of the randomized RESCUE-Japan LIMIT (Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-Japan Large Ischemic Core Trial), with enrollment November 2018 to September 2021, in which the primary outcome was the modified Rankin Scale (mRS) score at 90 days. Participants with a baseline ASPECTS 3-5 (on the basis of noncontrast CT and diffusion-weighted imaging) were randomized 1:1 to receive EVT plus best medical management (n = 100) or best medical management alone (n = 102). The primary outcome of the current study was cost-effectiveness, determined according to the incremental cost-effectiveness ratio (ICER). A decision model consisting of a short-term component (cycle length of 3 months) and a long-term Markov state transition component (cycle length of 1 year) was used to estimate expected lifetime costs and quality-adjusted life-years (QALYs) from health care and societal perspectives in the United States. Upper and lower willingness-to-pay (WTP) thresholds were set at $100 000 and $50 000 per QALY, respectively. A deterministic one-way sensitivity analysis to determine the impact of participant age and a probabilistic sensitivity analysis to assess the impact of parameter uncertainty were conducted. Results A total of 202 participants were included in the study (mean age, 76 years ± 10 [SD]; 112 male). EVT plus best medical management resulted in ICERs of $15 743 (health care perspective) and $19 492 (societal perspective). At the lower and upper WTP thresholds, EVT was cost-effective up to 85 and 90 years (health care perspective) and 84 and 89 years (societal perspective) of age, respectively. When analyzing participants with the largest infarcts (ASPECTS 3) separately, EVT was not cost-effective (ICER, $337 072 [health care perspective] and $383 628 [societal perspective]). Conclusion EVT was cost-effective for participants with an ASPECTS 4-5, but not for those with an ASPECTS 3. ClinicalTrials.gov registration no. NCT03702413 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Widjaja in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ospel JM, Kunz WG, McDonough RV, et al. Cost-effectiveness of Endovascular Treatment for Acute Stroke with Large Infarct: A United States Perspective. Radiology. 2023. PMID: 37787675. doi:10.1148/radiol.223320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。